US · ZYXI
Zynex, Inc.
- Sector
- Healthcare · Medical - Distribution
- Headquarters
- Englewood, CO 80112
- Website
- zynex.com
Price · as of 2024-12-31
—
Market cap 34.24M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $42.45 | — |
| Intrinsic Value(DCF) | $2.94 | — |
| Graham-Dodd Method(GD) | $0.94 | — |
| Graham Formula(GF) | $1.16 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.35 | $61.29 | $298.84 | $0.30 | $0.37 |
| 2011 | $0.34 | $37.79 | $282.72 | $0.53 | $2.23 |
| 2012 | $0.27 | $25.52 | $38.96 | $0.57 | $1.07 |
| 2013 | $0.23 | $56.57 | $0.00 | $0.00 | $7.52 |
| 2014 | $0.13 | $167.19 | $0.00 | $0.00 | $7.01 |
| 2015 | $0.30 | $37.46 | $0.00 | $0.00 | $0.00 |
| 2016 | $0.28 | $40.89 | $0.00 | $0.00 | $0.04 |
| 2017 | $3.59 | $194.03 | $34.25 | $1.18 | $16.83 |
| 2018 | $4.37 | $40.78 | $113.29 | $1.60 | $11.42 |
| 2019 | $12.74 | $47.20 | $422.19 | $0.93 | $12.95 |
| 2020 | $15.17 | $64.80 | $3,057.22 | $2.74 | $19.73 |
| 2021 | $5.19 | $66.17 | $5,385.86 | $3.30 | $27.60 |
| 2022 | $9.53 | $33.13 | $2,090.81 | $2.00 | $12.68 |
| 2023 | $12.86 | $37.80 | $534.69 | $2.09 | $6.57 |
| 2024 | $7.35 | $42.45 | $54.23 | $0.94 | $1.16 |
AI valuation
Our deep-learning model estimates Zynex, Inc.'s (ZYXI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $42.45
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.94
— upside
Graham-Dodd
$0.94
— upside
Graham Formula
$1.16
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ZYXI | Zynex, Inc. | $1.13 | 34.24M | +3,657% | +160% | -16% | +2% | 78.41 | 6.57 | 1.22 | 24.92 | — | 29.13 | 79.50% | 3.11% | 1.56% | 7.32% | 6.70% | 2.31% | 2.07 | 2.51 | 4.46 | 3.42 | 3.17 | -6667.00% | 436.00% | -2663.00% | 5.17% | 0.75 | 16.45% | 0.00% | 0.30% | 6.66% | 44.90 | 22.15 | 1.40 | 4.28 |
| ECOR | electroCore, Inc. | $4.74 | 35.95M | +2,323% | +16,707% | — | — | -8.88 | 13.99 | 4.19 | -8.96 | — | 13.99 | 84.97% | -48.30% | -47.20% | -158.63% | 945.74% | -65.00% | 0.55 | — | 1.78 | 1.46 | -0.06 | -5351.00% | 5709.00% | -5329.00% | -6.59% | -0.76 | 544.51% | 0.00% | 0.00% | 0.00% | -8.03 | -14.06 | 3.88 | -7.53 |
| EVAX | Evaxion Biotech A/S | $5.66 | 35.75M | +14,419% | -87% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| GBIO | Generation Bio Co. | $5.19 | 34.96M | +50% | -59% | — | — | -0.27 | 0.41 | 1.78 | 0.76 | -40.69 | 0.41 | 100.00% | -715.82% | -661.91% | -91.02% | -912.79% | -43.46% | 1.09 | — | 5.50 | 5.33 | -0.23 | 66.00% | 23692.00% | 5125.00% | -256.40% | -2.53 | -583.12% | 0.00% | 0.00% | 39.99% | 0.39 | 0.62 | -2.82 | -5.24 |
| HYPD | Eyenovia, Inc. Common Sto… | $5.92 | 33.7M | +564% | +70,178% | — | — | -0.03 | -0.10 | 23.10 | -0.23 | -0.21 | -0.10 | -6749.50% | -85004.58% | -86888.57% | 2432.03% | -1558.51% | -307.07% | -0.86 | -19.62 | 0.17 | 0.13 | -0.20 | 1253.00% | 141402.00% | 890.00% | -2286.39% | -1.88 | -968.35% | 0.00% | 0.00% | 0.00% | -0.21 | -0.34 | 182.16 | -122.68 |
| JSPR | Jasper Therapeutics, Inc. | $1.95 | 31.69M | — | — | — | — | -1.10 | 1.27 | — | -0.11 | — | 1.27 | 0.00% | — | — | -101.73% | 1104.03% | -81.55% | 0.03 | — | 4.98 | 4.70 | 0.93 | -2087.00% | — | 2067.00% | -80.64% | -4.11 | 914.55% | 0.00% | 0.00% | 0.00% | -0.11 | -0.13 | — | -3.88 |
| MODD | Modular Medical, Inc. | $0.49 | 27.27M | — | — | — | — | -1.66 | 1.83 | — | -1.09 | — | 1.83 | 0.00% | — | — | -131.58% | -459.49% | -115.69% | 0.05 | — | 10.69 | 10.41 | 0.71 | -3462.00% | — | 1636.00% | -58.31% | -12.43 | -439.34% | 0.00% | 0.00% | 13.57% | -1.00 | -1.04 | — | 2.40 |
| MURA | Mural Oncology plc | $2.08 | 36.03M | — | — | — | — | -0.48 | 0.44 | — | 0.60 | — | 0.44 | 0.00% | — | — | -63.57% | -2282.87% | -54.55% | 0.06 | — | 5.84 | 5.51 | 0.86 | -3902.00% | — | -3493.00% | -209.58% | -4.91 | -2123.95% | 0.00% | 0.00% | 0.00% | 0.54 | 0.58 | — | -1.84 |
| WGRX | Wellgistics Health, Inc. | $0.66 | 45.96M | — | — | — | — | -21.74 | 22.14 | 8.22 | -35.27 | -18.64 | -4.68 | 9.75% | -33.90% | -37.82% | -357.65% | -42.95% | -23.78% | 3.73 | -7.39 | 0.40 | 0.13 | -4.90 | 11667.00% | — | 35893.00% | -1.07% | -0.03 | -11.20% | 0.00% | 0.00% | 0.00% | -28.18 | -108.07 | 9.55 | 1.01 |
About Zynex, Inc.
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
- CEO
- Thomas Sandgaard
- Employees
- 1K
- Beta
- 1.01
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.94 ÷ —) − 1 = — (DCF, example).